S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
"How war impacts the stock market" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"How war impacts the stock market" (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
"How war impacts the stock market" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"How war impacts the stock market" (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
"How war impacts the stock market" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"How war impacts the stock market" (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Court battle over interstate travel targets Utah bus stops in Nevada, California
"How war impacts the stock market" (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
"How war impacts the stock market" (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Earnings Date, Estimates & Call Transcripts

$11.66
+0.03 (+0.26%)
(As of 06/2/2023 ET)
Compare
Today's Range
$11.41
▼
$11.83
50-Day Range
$6.68
▼
$13.48
52-Week Range
$5.84
▼
$14.45
Volume
193,172 shs
Average Volume
464,888 shs
Market Capitalization
$508.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.17
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Aug. 1Estimated
Actual EPS
(Feb. 28)
-$1.33 Beat By $0.17
Consensus EPS
(Feb. 28)
-$1.50
Last Year's Q1 EPS
(3/1/2022)
-$0.95
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

PHAT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PHAT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Phathom Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($1.34)($1.34)($1.34)
Q2 20231($1.37)($1.37)($1.37)
Q3 20231($1.37)($1.37)($1.37)
Q4 20231($1.32)($1.32)($1.32)
FY 20234($5.40)($5.40)($5.40)

PHAT Earnings Date and Information

Phathom Pharmaceuticals last released its earnings results on February 28th, 2023. The reported ($1.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.17. Phathom Pharmaceuticals has generated ($4.87) earnings per share over the last year (($4.87) diluted earnings per share). Earnings for Phathom Pharmaceuticals are expected to decrease in the coming year, from ($4.11) to ($4.34) per share. Phathom Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 1st, 2023 based off prior year's report dates.

Phathom Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/1/2023
(Estimated)		        
2/28/2023Q4 2022($1.50)($1.33)+$0.17($1.33)
11/8/2022Q3 2022($1.32)($1.32)($1.32)
8/2/2022Q2 2022($1.33)($1.33)($1.33)
5/10/2022Q1 2022($1.07)($1.07)($1.07)
3/1/2022Q4 2021($0.86)($0.95)($0.09)($0.95)
11/8/20219/30/2021($1.05)($0.98)+$0.07($0.98)
8/10/20216/30/2021($1.07)($1.00)+$0.07($1.00)
5/11/2021Q1 2021($1.11)($0.96)+$0.15($0.96)
3/29/202112/31/2020($1.01)($1.58)($0.57)($1.58)
11/10/20209/30/2020($0.67)($1.02)($0.35)($1.02)
8/6/20206/30/2020($0.62)($0.64)($0.02)($0.64)
5/12/20203/31/2020($0.72)($0.62)+$0.10($0.62)
3/19/2020Q4 2019($1.25)($3.97)($2.72)
11/25/2019Q3 2019($0.67)($1.07)($0.40)$7.16












Phathom Pharmaceuticals Earnings - Frequently Asked Questions

When is Phathom Pharmaceuticals's earnings date?

Phathom Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 1st, 2023 based off last year's report dates. Learn more on PHAT's earnings history.

Did Phathom Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Phathom Pharmaceuticals (NASDAQ:PHAT) reported ($1.33) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.50) by $0.17. Learn more on analysts' earnings estimate vs. PHAT's actual earnings.

How much profit does Phathom Pharmaceuticals generate each year?

Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded net income of -$197.72 million. PHAT has generated -$4.87 earnings per share over the last four quarters.

What is Phathom Pharmaceuticals's EPS forecast for next year?

Phathom Pharmaceuticals's earnings are expected to decrease from ($4.11) per share to ($4.34) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:PHAT) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -